scholarly journals Numerical modelling of blood rheology and platelet activation through a stenosed left coronary artery bifurcation

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0259196
Author(s):  
David G. Owen ◽  
Diana C. de Oliveira ◽  
Emma K. Neale ◽  
Duncan E. T. Shepherd ◽  
Daniel M. Espino

Coronary bifurcations are prone to atherosclerotic plaque growth, experiencing regions of reduced wall shear stress (WSS) and increased platelet adhesion. This study compares effects across different rheological approaches on hemodynamics, combined with a shear stress exposure history model of platelets within a stenosed porcine bifurcation. Simulations used both single/multiphase blood models to determine which approach best predicts phenomena associated with atherosclerosis and atherothrombosis. A novel Lagrangian platelet tracking model was used to evaluate residence time and shear history of platelets indicating likely regions of thrombus formation. Results show a decrease in area of regions with pathologically low time-averaged WSS with the use of multiphase models, particularly in a stenotic bifurcation. Significant non-Newtonian effects were observed due to low-shear and varying hematocrit levels found on the outer walls of the bifurcation and distal to the stenosis. Platelet residence time increased 11% in the stenosed artery, with exposure times to low-shear sufficient for red blood cell aggregation (>1.5 s). increasing the risk of thrombosis. This shows stenotic artery hemodynamics are inherently non-Newtonian and multiphase, with variations in hematocrit (0.163–0.617) and elevated vorticity distal to stenosis (+15%) impairing the function of the endothelium via reduced time-averaged WSS regions, rheological properties and platelet activation/adhesion.

Author(s):  
Л.Н. Катюхин

Рассмотрены условия формирования агрегатов в сосудах. Представлена история изучения феномена обратимой агрегации эритроцитов. Дискутируется целесообразность терапевтической коррекции агрегации эритроцитов при патологии. This review contains the history of the reversible aggregation erythrocytes phenomenon study. The conditions of aggregates formation in vessels with low shear stress are discussed. The assumption is made on the feasibility of reducing еrythrocytes aggregation for correcting blood rheological behavior in the pathology.


2003 ◽  
Vol 13 (6) ◽  
pp. 305-312 ◽  
Author(s):  
G.A.M. Pop ◽  
W.J. Hop ◽  
L. Moraru ◽  
M. van der Jagt ◽  
J. Quak ◽  
...  

AbstractRed blood cell aggregation (RBCa) is a sensitive inflammation marker. RBCa determination from erythrocyte sedimentation rate, ESR, is used since long, but is unspecific unless corrected for hematocrit, Ht. Whole blood viscosity measurement at low shear rate is also sensitive to RBCa but is cumbersome to apply. To investigate whether electrical blood impedance, being sensitive to spatial red cell distribution, can be a good alternative to determine RBCa in low shear conditions. Blood was collected from 7 healthy volunteers. From each 16 different samples were prepared with 4 different Ht’s and with 4 different fibrinogen concentrations. Viscosity was measured at low shear rate (4.04 s-1) with a rotational viscometer at 37˚C. Electrical blood impedance was measured during similar shear conditions and temperature in a specially designed cuvette. ESR was determined according to Westergren. A logarithmic increase of viscosity as well as of capacitance, Cm, is seen when fibrinogen rises and an exponential increase when Ht rises. However, ESR shows a logarithmic decrease with increasing Ht and an exponential increase when fibrinogen rises. The viscosity could be accurately described using an exponential model. Under similar low shear conditions and temperature in-vitro, either whole blood viscosity or electrical blood capacitance reflect red blood cell aggregation due to fibrinogen and Ht variation in a similar way.


Blood ◽  
2019 ◽  
Vol 134 (25) ◽  
pp. 2304-2317 ◽  
Author(s):  
Marie Bellio ◽  
Cédric Garcia ◽  
Thomas Edouard ◽  
Sophie Voisin ◽  
Benjamin G. Neel ◽  
...  

Abstract Src homology 2 domain–containing phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a ubiquitous protein tyrosine phosphatase that is a critical regulator of signal transduction. Germ line mutations in the PTPN11 gene responsible for catalytic gain or loss of function of SHP2 cause 2 disorders with multiple organ defects: Noonan syndrome (NS) and NS with multiple lentigines (NSML), respectively. Bleeding anomalies have been frequently reported in NS, but causes remain unclear. This study investigates platelet activation in patients with NS and NSML and in 2 mouse models carrying PTPN11 mutations responsible for these 2 syndromes. Platelets from NS mice and patients displayed a significant reduction in aggregation induced by low concentrations of GPVI and CLEC-2 agonists and a decrease in thrombus growth on a collagen surface under arterial shear stress. This was associated with deficiencies in GPVI and αIIbβ3 integrin signaling, platelet secretion, and thromboxane A2 generation. Similarly, arterial thrombus formation was significantly reduced in response to a local carotid injury in NS mice, associated with a significant increase in tail bleeding time. In contrast, NSML mouse platelets exhibited increased platelet activation after GPVI and CLEC-2 stimulation and enhanced platelet thrombotic phenotype on collagen matrix under shear stress. Blood samples from NSML patients also showed a shear stress–dependent elevation of platelet responses on collagen matrix. This study brings new insights into the understanding of SHP2 function in platelets, points to new thrombopathies linked to platelet signaling defects, and provides important information for the medical care of patients with NS in situations involving risk of bleeding.


Author(s):  
Dong Han ◽  
Jiafeng Zhang ◽  
Bartley Griffith ◽  
Zhongjun Wu

Abstract Shear-induced platelet activation is one of the critical outcomes when blood is exposed to elevated shear stress. Excessively activated platelets in the circulation can lead to thrombus formation and platelet consumption, resulting in serious adverse events such as thromboembolism and bleeding. While experimental observations reveal that it is related to the shear stress level and exposure time, the underlying mechanism of shear-induced platelet activation is not fully understood. Various models have been proposed to relate shear stress levels to platelet activation, yet most are modified from the empirically calibrated power-law model. Newly developed multiscale platelet models are tested as a promising approach to capture a single platelet's dynamic shape during activation, but it would be computationally expensive to employ it for a large-scale analysis. This paper summarizes the current numerical models used to study the shear-induced platelet activation and their computational applications in the risk assessment of a particular flow pattern and clot formation prediction.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 490-490
Author(s):  
Julio A. Chirinos ◽  
Maike Tiede ◽  
Wenche Jy ◽  
Carlos J. Bidot ◽  
Lawrence L. Horstman ◽  
...  

Abstract Background: The association between antiphospholipids antibodies (APLA) and thrombosis is controversial. Positive APLA are frequently noted in patients without thrombosis. Many mechanisms have been proposed to explain how APLA might induce thrombosis. A leading hypothesis is that platelet activation is central to thrombosis in APLA positive patients, but endothelial injury is also widely proposed. We aimed to evaluate these two theories by measuring endothelial microparticles (EMP) and platelet microparticles (PMP), which are sensitive markers of endothelial and platelet activation respectively, in patients with positive APLA, with and without thrombosis to determine whether these biomarkers correlate with thombotic risk in this population. Study Subjects and Methods: We studied 80 patients referred to our clinic having positive APLA. Positive IgM or IgG against cardiolipin or β2 glycoprotein I were confirmed at least twice by ELISA. Sixty of them had a history of obstetric complications or thrombosis, including TIA, stroke, myocardial infarction, deep venous thrombosis or pulmonary embolism. The remaining 20 patients had positive APLA without history of thrombosis. We excluded all patients who had a thrombotic event within 90 days prior to obtaining the sample to avoid the possible effect of acute thrombus formation on EMP and PMP. We measured EMP, PMP, and P-selectin expression by flow cytometry. PMP were defined as CD31+/CD42+ particles and EMP were defined as CD62E+ particles <1.5 μm in diameter. We compared EMP and PMP in these two patient groups to determine which markers correlate well with thrombotic events. Due to the non-normal distribution of PMP levels, values were log-transformed before comparison between the 2 groups and are expressed as geometric means. Results: Levels of EMP were significantly higher in patients with thrombosis (681 counts/μL) compared to normal controls (195 counts/μL; p<0.0001). EMP were also higher in patients with positive APLA and no thrombosis (488 counts/μL) than normal controls (p=0.003). EMP were not significantly different between APLA positive patients with vs. without thrombosis (p=0.86). In contrast, levels of PMP were significantly higher in patients with thrombosis (3305 counts/μL) than without thrombosis (1170 counts/μL; p =0.03) or healthy controls (620 counts/μL; p=0.01). No significant differences in PMP were found between patients without thrombosis and normal controls (p=NS). Results of platelet activation marker P-selectin were parallel to those of PMP. After adjusting for age, and risk factors for arterial thrombosis (dyslipidemia, diabetes mellitus, hypertension, and current smoking) the difference in PMP between patients with/without thrombosis persisted (p=0.04). Conclusion: EMP are elevated in patients with positive APLA regardless of whether they had thrombosis or not. However, only APLA positive patients with thrombosis had elevated PMP. These results suggest that endothelial injury is widely present in APLA positive patients, but that risk of thrombosis depends mainly on platelet activation


Blood ◽  
1995 ◽  
Vol 85 (3) ◽  
pp. 705-711 ◽  
Author(s):  
J Harsfalvi ◽  
JM Stassen ◽  
MF Hoylaerts ◽  
E Van Houtte ◽  
RT Sawyer ◽  
...  

Calin from the saliva of the medicinal leech, Hirudo medicinalis, is a potent inhibitor of collagen mediated platelet adhesion and activation. In addition to inhibition of the direct platelet-collagen interaction, we presently demonstrate that binding of von Willebrand to coated collagen can be prevented by Calin, both under static and flow conditions in agreement with the occurrence of binding of Calin to collagen, confirmed by Biospecific Interaction Analysis. To define whether Calin acted by inhibiting the platelet-collagen or the platelet- von Willebrand factor (vWF)-collagen-mediated thrombus formation, platelet adhesion to different types of collagens was studied in a parallel-plate flow chamber perfused with whole blood at different shear rates. Calin dose-dependently prevented platelet adhesion to the different collagens tested both at high- and low-shear stress. The concentration of Calin needed to cause 50% inhibition of platelet adhesion at high-shear stress was some fivefold lower than that needed for inhibition of vWF-binding under similar conditions, implying that at high-shear stress, the effect of Calin on the direct platelet- collagen interactions, suffices to prevent thrombus formation. Platelet adhesion to extracellular matrix (ECM) of cultured human umbilical vein endothelial cells was only partially prevented by Calin, and even less so at a high-shear rather than a low-shear rate, whereas the platelet binding to coated vWF and fibrinogen were minimally affected at both shear rates. Thus, Calin interferes with both the direct platelet- collagen interaction and the vWF-collagen binding. Both effects may contribute to the inhibition of platelet adhesion in flowing conditions, although the former seems to predominate.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 114-114
Author(s):  
Alessandro Zarpellon ◽  
Patrizia Marchese ◽  
Antonella Zampolli ◽  
Grazia Loredana Mendolicchio ◽  
Zaverio M. Ruggeri

Abstract Generation of α-thrombin (FIIa) in response to vascular injury is a key mechanism influencing thrombus formation. Platelet activation by FIIa is mediated by different protease activated receptors (PARs), although the most abundant FIIa binding site on platelets, but not a substrate for proteolysis, is glycoprotein (GP) Ibα in the GPIb-IX-V complex. The functional role of GPIbα in mediating/regulation thrombin functions relative to that of different PARs remains unclear. The goal of these studies was to define how binding to GPIbα can modulate FIIa functions. In mouse platelets we replaced endogenous GPIbα with either its human wild type counterpart (huGPIbα-WT) or with huGPIbα mutated at key residues involved in thrombin binding (D277N, Y276-8-9/F). Because these two mutations resulted in an undistinguishable phenotype, they are designated collectively as huGPIbα-Mut hereon. Mice expressing huGPIbα, WT or Mut, were evaluated in intravital models of arterial thrombosis induced by a ferric chloride-induced carotid artery lesion and venous thromboembolism induced by intravenous α-thrombin injection. Moreover, the blood of huGPIbα WT or Mut mice was also tested in an ex vivo model of thrombus formation upon perfusion over a thrombogenic surface under controlled flow conditions and platelets were evaluated for their responses to FIIa-induced activation. Mice expressing huGPIbα - WT or Mut - have comparable platelet counts and GPIbα surface density. Moreover, huGPIbα-WT platelets bind FIIa similarly than their normal human control counterpart, while huGPIbα-Mut platelets have essentially no detectable FIIa binding. Upon FIIa stimulation, which on mouse platelets is mediated by PAR4, aggregation and Ca2+ transients were significantly enhanced in huGPIbα-Mut as compared to huGPIbα-WT. In contrast, blocking FIIa binding to GPIbα on human platelets essentially abolished FIIa mediated activation, which in human occurs predominantly through PAR1. These results are compatible with the conclusion that, in mice, GPIbα is a competitive inhibitor of FIIa for PAR4-mediated functions. In the presence of metabolically inactive (PGE1 treated) huGPIbα-Mut washed platelets, the clotting time of a purified fibrinogen solution was significantly shorter when triggered by relative high concentration of FIIa (4 nM), but pronouncedly prolonged at a lower FIIa concentration (0.5 nM). Clot visualization showed a much more structured fibrin mesh in the presence of huGPIbα-WT platelets, which was lost with in the presence of huGPIbα-Mut platelets. Mutant mice tested in a model of carotid artery injury exhibited a pronounced prothrombotic phenotype, with a shorter time to occlusion. However they were protected from death induced by I.V. injection of α-thrombin. In ex vivo perfusion studies, the total volume of platelet aggregates formed in huGPIbα-Mut mouse blood exposed to acid-insoluble fibrillar collagen type I was slightly bigger than in huGPIbα-WT mice, but the number of thrombi was increased and their individual size smaller. These huGPIbα-Mut platelets exhibited clear signs of increased activation, as visualized by scanning electron microscopy (SEM). Strikingly, fibrin was almost totally absent in the huGPIbα-Mut thrombi. This was in striking contrast with what observed in huGPIbα-WT mice, in which the surface of platelet thrombi with directly and tightly connected with thick fibrin fibers as visualized by scanning electron microscopy. Possibly because of the reduced platelet membrane-fibrin fibril connection in huGPIbα-Mut platelets, these mice were significantly less susceptible to death when injected with an α-thrombin dose that caused 80% mortality plus in huGPIbα-WT mice. Thus, mice whose platelets have defective α-thrombin binding to GPIbα have a prothrombotic phenotype in high shear stress flow arteries and are protected from thromboembolic death in the low shear stress venous circulation. Our findings identify GPIbα as a relevant FIIa activity modulator in hemostasis and thrombosis through distinct and opposite mechanisms affecting platelet activation (The Yin) and fibrin formation (The Yang). Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 40 (11) ◽  
pp. 2678-2685
Author(s):  
Mohammed N. Meah ◽  
Jennifer Raftis ◽  
Simon J. Wilson ◽  
Vidya Perera ◽  
Samira M. Garonzik ◽  
...  

Objective: PAR (protease-activated receptor)-4 antagonism has antiplatelet effects under conditions of high shear stress. We aimed to establish whether PAR4 antagonism had additive antithrombotic activity in the presence of factor Xa inhibition in an ex vivo model of acute arterial injury. Approach and Results: Fifteen healthy volunteers (29±6 years, 7 women) completed a phase zero double-blind randomized controlled crossover trial. Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured following blood perfusion of low shear and high shear stress chambers. Upstream of the chambers, extracorporeal blood was admixed with (1) vehicle, (2) low-dose apixaban (20 ng/mL), (3) high-dose apixaban (80 ng/mL), (4) BMS-986141 (400 ng/mL), (5) BMS-968141 and low-dose apixaban, or (6) BMS-968141 and high-dose apixaban in 6 sequential studies performed in random order. Compared with vehicle, BMS-986141 demonstrated selective inhibition of PAR4-AP (agonist peptide)–stimulated platelet aggregation, platelet-monocyte aggregates, and P-selectin expression ( P ≤0.01 for all). Total thrombus area was reduced under both low shear and high shear stress conditions for all drug infusions ( P <0.0001 for all versus vehicle). BMS-968141 reduced total (≤44.4%) and platelet-rich (≤39.3%) thrombus area, whereas apixaban reduced total (≤42.9%) and fibrin-rich (≤31.6%) thrombus area. Combination of BMS-986141 with apixaban caused a further modest reduction in total thrombus area (9.6%–12.4%), especially under conditions of high shear stress ( P ≤0.027). Conclusions: In the presence of factor Xa inhibition, PAR4 antagonism with BMS-986141 further reduces thrombus formation, especially under conditions of high shear stress. This suggests the potential for additive efficacy of combination PAR4 antagonism and factor Xa inhibition in the prevention of atherothrombotic events.


1999 ◽  
Vol 121 (5) ◽  
pp. 494-501 ◽  
Author(s):  
D. Tang ◽  
J. Yang ◽  
C. Yang ◽  
D. N. Ku

Arteries with high-grade stenoses may compress under physiologic conditions due to negative transmural pressure caused by high-velocity flow passing through the stenoses. To quantify the compressive conditions near the stenosis, a nonlinear axisymmetric model with fluid–wall interactions is introduced to simulate the viscous flow in a compliant stenotic tube. The nonlinear elastic properties of the tube (tube law) are measured experimentally and used in the model. The model is solved using ADINA (Automatic Dynamic Incremental Nonlinear Analysis), which is a finite element package capable of solving problems with fluid–structure interactions. Our results indicate that severe stenoses cause critical flow conditions such as negative pressure and high and low shear stresses, which may be related to artery compression, plaque cap rupture, platelet activation, and thrombus formation. The pressure field near a stenosis has a complex pattern not seen in one-dimensional models. Negative transmural pressure as low as −24 mmHg for a 78 percent stenosis by diameter is observed at the throat of the stenosis for a downstream pressure of 30 mmHg. Maximum shear stress as high as 1860 dyn/cm2 occurs at the throat of the stenoses, while low shear stress with reversed direction is observed right distal to the stenosis. Compressive stresses are observed inside the tube wall. The maximal principal stress and hoop stress in the 78 percent stenosis are 80 percent higher than that from the 50 percent stenosis used in our simulation. Flow rates under different pressure drop conditions are calculated and compared with experimental measurements and reasonable agreement is found for the prebuckling stage.


Sign in / Sign up

Export Citation Format

Share Document